1265 related articles for article (PubMed ID: 27871992)
1. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
2. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
3. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
Kim J; Cho H; Lim DK; Joo MK; Kim K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
[TBL] [Abstract][Full Text] [Related]
4. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
5. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
8. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
Zhang Y; Ho SH; Li B; Nie G; Li S
Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
10. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
[TBL] [Abstract][Full Text] [Related]
11. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
12. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
Natfji AA; Ravishankar D; Osborn HMI; Greco F
J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
[TBL] [Abstract][Full Text] [Related]
13. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
15. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
[TBL] [Abstract][Full Text] [Related]
16. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
17. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on the past, present, and future of cancer nanomedicine.
Youn YS; Bae YH
Adv Drug Deliv Rev; 2018 May; 130():3-11. PubMed ID: 29778902
[TBL] [Abstract][Full Text] [Related]
20. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
